PDF(Pubmed)
Abstract：
Cancer initiation and progression have been associated with dysregulated long non-coding RNA (lncRNA) expression. However, the lncRNA expression profile in aggressive B-cell non-Hodgkin lymphoma (NHL) has not been comprehensively characterized. This systematic review aims to evaluate the role of lncRNAs as a biomarker to investigate their future potential in the diagnosis, real-time measurement of response to therapy and prognosis in aggressive B-cell NHL. We searched PubMed, Web of Science, Embase and Scopus databases using the keywords \"long non-coding RNA\", \"Diffuse large B-cell lymphoma\", \"Burkitt\'s lymphoma\" and \"Mantle cell lymphoma\". We included studies on human subjects that measured the level of lncRNAs in samples from patients with aggressive B-cell NHL. We screened 608 papers, and 51 papers were included. The most studied aggressive B-cell NHL was diffuse large B-cell lymphoma (DLBCL). At least 79 lncRNAs were involved in the pathogenesis of aggressive B-cell NHL. Targeting lncRNAs could affect cell proliferation, viability, apoptosis, migration and invasion in aggressive B-cell NHL cell lines. Dysregulation of lncRNAs had prognostic (e.g. overall survival) and diagnostic values in patients with DLBCL, Burkitt\'s lymphoma (BL), or mantle cell lymphoma (MCL). Furthermore, dysregulation of lncRNAs was associated with response to treatments, such as CHOP-like chemotherapy regimens, in these patients. LncRNAs could be promising biomarkers for the diagnosis, prognosis and response to therapy in patients with aggressive B-cell NHL. Additionally, lncRNAs could be potential therapeutic targets for patients with aggressive B-cell NHL like DLBCL, MCL or BL.
摘要：
癌症的发生和进展与长链非编码RNA(lncRNA)表达失调有关。然而,侵袭性B细胞非霍奇金淋巴瘤(NHL)的lncRNA表达谱尚未得到全面表征.本系统综述旨在评估lncRNAs作为生物标志物的作用，以研究其在诊断中的未来潜力。实时测量侵袭性B细胞NHL对治疗和预后的反应。我们搜索了PubMed,WebofScience,Embase和Scopus数据库使用关键字“长非编码RNA”，“弥漫性大B细胞淋巴瘤”，“伯基特淋巴瘤”和“套细胞淋巴瘤”。我们包括对人类受试者的研究，这些研究测量了侵袭性B细胞NHL患者样品中lncRNAs的水平。我们筛选了608篇论文，包括51篇论文。研究最多的侵袭性B细胞NHL是弥漫性大B细胞淋巴瘤（DLBCL）。至少有79个lncRNAs参与侵袭性B细胞NHL的发病机制。靶向lncRNAs可以影响细胞增殖，生存能力，凋亡，侵袭性B细胞NHL细胞系的迁移和侵袭。lncRNAs的失调在DLBCL患者中具有预后（例如总生存期）和诊断价值，伯基特淋巴瘤(BL),或套细胞淋巴瘤（MCL）。此外，lncRNAs的失调与对治疗的反应有关，如CHOP样化疗方案，在这些患者中。LncRNAs可能是诊断的有希望的生物标志物，侵袭性B细胞NHL患者的预后和治疗反应。此外,lncRNAs可能是侵袭性B细胞NHL如DLBCL患者的潜在治疗靶点，MCL或BL。
